Losartan protects the heart against ischemia reperfusion injury: Sirtuin3 involvement

Journal of Pharmacy and Pharmaceutical Sciences

Volumn 18, Issue 1, 2015, Pages 112-123

  Klishadi, Mohsen Sharifi ^a   Zarei, Farideh ^a   Hejazian, Seyyed Hassan ^a   Moradi, Ali ^a   Hemati, Mahdieh ^a   Safari, Fatemeh ^a  

^a SHAHID SADOUGHI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

CATALASE; LOSARTAN; MANGANESE SUPEROXIDE DISMUTASE; MESSENGER RNA; SIRTUIN 3; THIOREDOXIN 1; CARDIOTONIC AGENT; THIOREDOXIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; GENE EXPRESSION; GENETIC TRANSCRIPTION; HEART INFARCTION SIZE; HEART LEFT VENTRICLE; HEART PROTECTION; HEART RATE; HEART RIGHT VENTRICLE; HEART VENTRICLE EXTRASYSTOLE; HEART VENTRICLE TACHYCARDIA; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; PROTEIN BLOOD LEVEL; PROTEIN CONTENT; QUANTITATIVE ANALYSIS; RAT; REAL TIME POLYMERASE CHAIN REACTION; REPERFUSION INJURY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING; ANIMAL; DOSE RESPONSE; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MYOCARDIAL REPERFUSION INJURY; PATHOPHYSIOLOGY; UPREGULATION; WISTAR RAT;

ANIMALS; BLOTTING, WESTERN; CARDIOTONIC AGENTS; CATALASE; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION REGULATION; LOSARTAN; MALE; MYOCARDIAL REPERFUSION INJURY; RATS; RATS, WISTAR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIRTUIN 3; THIOREDOXINS; UP-REGULATION;

EID: 84931269641     PISSN: None     EISSN: 14821826     Source Type: Journal    
DOI: 10.18433/j3xg7t     Document Type: Article

References (38)

1. Hausenloy DJ. and Yellon DM. Myocardial ischemia-reperfusion injury: a neglected therapeutic target. J Clin Invest, 123:92-100, 2013.
2. Dorweiler B., Pruefer D., Andrasi TB., Maksan SM., Schmiedt W., Neufang A., Vah CF. Ischemia-reperfusion injury Patophysiology and clinical implications. Eur J Trauma Emerg Surg, 33:600–612, 2007.
3. Yang BC., Philips MI., Ambuehl PE., Shen BS. Increase in angiotensin II type 1 receptor expression immediately after ischemiareperfusion in isolated rat hearts. Circulation, 96:922-926, 1997.
4. Baker KM., Booz GW., Dostal DE. Cardiac actions of angiotensin II: role of an intracardiacrenin-angiotensin system. Annu Rev Physiol, 54:227–241, 1992.
5. Sladek T., Sladkova J., Kolar F., Papousek F., Cicutti N., Korecky B., Rakusan K. The effect of AT1 receptor antagonist on chronic cardiac response to coronary artery ligation in rats. Cardiovasc Res, 31:568–76, 1996.
6. Safari F., Hajizadeh S., Shekarforoush S., Bayat G., Foadoddini M., Khoshbaten A. Influence of ramiprilat and losartan on ischemia reperfusion injury in rat hearts. J Renin-Angiotensin-Aldosterone Syst, 13:29–35, 2012.
7. Zhu B., Sun Y., Sievers RE., Browne AE., Pulukurthy S., Sudhir K., Lee RJ., Chou TM., Chatterjee K., Parmley WW. Comparative effects of pretreatment with captopril and losartan on cardiovascular protection in a rat model of ischemia-reperfusion. J Am Coll Cardiol, 35:787–95, 2000.
8. Mollnau H., Wendt M., Szöcs K., Lassègue B., Schulz E., Oelze M., Li H., Bodenschatz M., August M., Kleschyov AL., Tsilimingas N., Walter U., Förstermann U., Meinertz T., Griendling K., Münzel T.Effects of angiotensin II infusion on the expression and function of NAD (P) H oxidase and components of nitric oxide/cGMP signaling. Circ Res,90:E58–65, 2002.
9. Safari F., Hajiadeh S., Moshtaghion SM., Forouzandeh Moghadam M., Shekarforoush S., Bayat G., Mazlum R., Sattarian L. Effect of losartan on NOX2 transcription following acute myocardial ischemia-reperfusion. Physiol Pharmacol, 16:44-53, 2012.
10. Messadi-Laribi E., Griol-Charhbili V., Pizard A., Vincent MP., Heudes D., Meneton P., Alhenc-Gelas F., Richer C. Tissue kallikrein is involved in the cardioprotective effect of AT1-receptor blockade in acute myocardial ischemia. J Pharmacol Exp Ther, 323:210–216, 2007.
11. Kelly GS. A review of the sirtuin system, its clinical implications, and the potential role of dietary activators like resveratrol: part 2, Altern Med Rev, 15:313-328, 2010.
12. Lavu S., Boss O., Elliott PJ., Lambert PD. Sirtuins-novel therapeutic targets to treat ageassociated diseases. Nat Rev Drug Discov, 7:841-853, 2008.
13. Pillai VB., Sundaresan NR., Jeevanandam V., Gupta MP. Mitochondrial SIRT3 and heart disease. Cardiovasc Res, 88:250–256, 2010.
14. Jin L., Galonek H., Israelian K., Choy W., Morrison M., Xia Y., Wang X., Xu Y., Yang Y., Smith JJ., Hoffmann E., Carney DP., Perni RB., Jirousek MR., Bemis JE., Milne JC., Sinclair DA., Westphal CH. Biochemical characterization, localization, and tissue distribution of the longer form of mouse SIRT3. Protein Sci,18:514–525, 2009.
15. Onyango P., Celic I., McCaffery JM., Boeke JD., Feinberg AP. SIRT3, a human SIR2 homologue, is an NAD-dependent deacetylase localized to mitochondria. Proc Natl Acad Sci U S A, 15:13653-8, 2002.
16. Tompkins AJ., Burwell LS., Digerness SB., Zaragoza C., Holman WL., Brookes PS. Mitochondrial dysfunction in cardiac ischemiareperfusion injury. ROS from complex I, without inhibition. Biochim Biophys Acta, 1762:223-231, 2006.
17. Newman JC., He W., Verdin E. Mitochondrial protein acylation and intermediary metabolism: regulation by sirtuins and implications for metabolic disease. J Biol Chem, 287:42436-43, 2012.
18. Bharathi SS., Zhang Y., Mohsen AW., Uppala R., Balasubramani M., Schreiber E., Uechi G., Beck ME., Rardin MJ., Vockley J., Verdin E., Gibson BW., Hirschey MD., Goetzman ES. Sirtuin 3 (SIRT3) protein regulates long-chain acyl-CoA dehydrogenase by deacetylating conserved lysines near the active site. J Biol Chem, 288:33837-47, 2013.
19. Samant SA., Zhang HJ., Hong Z., Pillai VB., Sundaresan NR., Wolfgeher D., Archer SL., Chan DC., Gupta MP. SIRT3 deacetylates and activates OPA1 to regulate mitochondrial dynamics during stress. Mol Cell Biol, 34:807-19, 2014.
20. Sundaresan NR., Gupta M., Kim G., Rajamohan SB., Isbatan A., Gupta MP. Sirt3 blocks the cardiac hypertrophic response by augmenting Foxo3a-dependent antioxidant defense mechanisms in mice. J Clin Invest, 119:2758, 2009.
21. Qiu X., Brown K., Hirschey MD., Verdin E., Chen D. Calorie restriction reduces oxidative stress by SIRT3-mediated SOD2 activation. Cell Metab, 12:662–7, 2010.
22. Sundaresan NR., Samant SA., Pillai VB., Rajamohan SB., Gupta MP. SIRT3 is a stressresponsive deacetylase in cardiomyocytes that protects cells from stress-mediated cell death by deacetylation of Ku70. Mol Cell Biol, 28:6384-401, 2008.
23. Benigni A., Corna D., Zoja C., Sonzogni A., Latini R., Salio M., Conti S., Rottoli D., Longaretti L., Cassis P., Morigi M., Coffman TM., Remuzzi G. Disruption of the Ang II type 1 receptor promotes longevity in mice. J Clin Invest, 119:524–530, 2009.
24. Curtis MJ., Hancox JC., Farkas A., Wainwright CL., Stables CL., Saint DA., Clements-Jewery H., Lambiase PD., Billman GE., Janse MJ., Pugsley MK., Ng GA., Roden DM., Camm AJ., Walker MJ. The Lambeth Conventions (II): guidelines for the study of animal and human ventricular and supraventricular arrhythmias. Pharmacol Ther, 139:213-248, 2013.
25. Zeng L., Yang Y., Hu Y., Sun Y., Du Z., Xie Z., Zhou T., Kong W. Age-related decrease in the mitochondrial sirtuin deacetylase Sirt3 expression associated with ROS accumulation in the auditory cortex of the mimetic aging rat model. PLoS One, 9:e88019, 2014.
26. Schwer B., North BJ., Frye RA., Ott M., Verdin E. The human silent information regulator (Sir)2 homologue hSIRT3 is a mitochondrial nicotinamide adenine dinucleotide-dependent deacetylase. J Cell Biol, 158:647-657, 2002.
27. Orrenius S., Gogvadze V., Zhivotovsky B. Mitochondrial oxidative stress implications for cell death. Annu Rev Pharmacol Toxicol, 47: 143-83, 2007.
28. Tompkins AJ., Burwell LS., Digerness SB., Zaragoza C., Holman WL., Brookes PS. Mitochondrial dysfunction in cardiac ischemia-reperfusion injury. ROS from complex I, without inhibition. Biochim Biophys Acta, 1762: 223-31, 2006.
29. Hafner AV., Dai J., Gomes AP., Xiao CY., Palmeira CM., Rosenzweig A., Sinclair DA. Regulation of the mPTP by SIRT3-mediated deacetylation of CypD at lysine 166 suppresses age-related cardiac hypertrophy. Aging (Albany NY), 2:914-23, 2010.
30. Mukherjee S., Ray D., Lekli I., Bak I., Tosaki A., Das DK. Effects of Longevinex (modified resveratrol) on cardioprotection and its mechanisms of action. Can J Physiol Pharmacol. 88:1017-25, 2010.
31. Das S., Mitrovsky G., Vasanthi HR., Das DK. Anti aging properties of a grape-derived antioxidant are regulated by mitochondrial balance of fusion and fission leading to mitophagy triggered by a signaling network of Sirt1-Sirt3-Foxo3-PINK1-PARKIN. Oxid Med Cell Longev,2014:345105, 2014
32. Porter GA., Urciuoli WR., Brookes PS., Nadtochiy SM. SIRT3 deficiency exacerbates ischemia-reperfusion injury: implication for aged hearts. Am J Physiol Heart Circ Physiol, 306:H1602-9, 2014.
33. Safari F., Anvari Z., Moshtaghioun S., Javan M., Bayat G., Foroshs S., Hekmatimoghaddam S. Differential expression of cardiac uncoupling proteins 2 and 3 in response to myocardial ischemia-reperfusion in rats. Life Sci, 98:68-74, 2014.
34. Fert-Bober J., Basran RS., Sawicka J., Sawicki G. Effect of duration of ischemia on myocardial proteome in ischemia/reperfusion injury. Proteomics, 8:2543-55, 2008.
35. Lindahl T., Satoh MS., Poirier GG., Klungland A. Posttranslational modification of poly (ADPribose) polymerase induced by DNA single strand breaks. Trends Biochem Sci, 20: 405-411, 1995.
36. Turoczi T, Chang VW, Engelman RM, Maulik N, Ho YS, Das DK. Thioredoxin redox signaling in the ischemic heart: an insight with transgenic mice overexpressing Trx1. J Mol Cell Cardiol 35:695-704, 2003.
37. Das DK. Thioredoxin regulation of ischemic preconditioning. Antioxid Redox Signal. 6:405-12, 2004.
38. Yamamoto M, Yang G, Hong C, Liu J, Holle E, Yu X et al. Inhibition of endogenous thioredoxin in the heart increases oxidative stress and cardiac hypertrophy. J Clin Invest 112:1395-406, 2003.